Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
lunedì, agosto 31
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Haleon PLC
HLN
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$10.11
0.07
0.7%
In chiusura: Aug 27, 5:00 PM EST
$10.11
0.07
0.7%
Pre-mercato: 4:00 AM EST
Get Report
Panoramica
Notizie
Previsioni utili
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Dividendi
Confronta
Opzioni
Rapporto azionario
Haleon Financials
Haleon (HLN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Haleon H1 Adj. EPS $0.14 Up From $0.12 YoY, Sales $7.533B Beat $3.600B Estimate
Haleon (NYSE:HLN) reported quarterly earnings of $0.14 per share. This is a 16.67 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $7.533 billion
Benzinga Newsdesk
Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025
Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains weighted to the second half.
Vandana Singh
PRO
Haleon Sees FY25 Organic Revenue Growth Of 4%-6%, Allocates GBP500M For Share Buybacks
Benzinga Newsdesk
PRO
Haleon FY Adjusted EPS GBp17.9 Up From GBp17.3 YoY, Sales GBP11.2B Down From GBP11.3B YoY
Benzinga Newsdesk
Earnings Scheduled For February 27, 2025
Benzinga Insights
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business
Dr. Reddy's Q3 FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.
Vandana Singh
Privacy Manager